Luigi Cavanna

9.8k total citations · 2 hit papers
217 papers, 4.7k citations indexed

About

Luigi Cavanna is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Luigi Cavanna has authored 217 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 38 papers in Pathology and Forensic Medicine. Recurrent topics in Luigi Cavanna's work include Lymphoma Diagnosis and Treatment (29 papers), Hepatocellular Carcinoma Treatment and Prognosis (20 papers) and Cancer Treatment and Pharmacology (20 papers). Luigi Cavanna is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), Hepatocellular Carcinoma Treatment and Prognosis (20 papers) and Cancer Treatment and Pharmacology (20 papers). Luigi Cavanna collaborates with scholars based in Italy, United States and Spain. Luigi Cavanna's co-authors include Fabio Fornari, Giuseppe Civardi, Daniele Vallisa, Claudia Biasini, Massimo Ambroggi, Raffaella Bertè, M. Stasi, Cinzia Del Giovane, G. Sbolli and L Buscarini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Luigi Cavanna

207 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

2009 446 citations Luigi Cavanna, Sandro Barni et al. profile →
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature

2015 376 citations Claudia Biasini, Fabio Fornari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luigi Cavanna Italy	35	2.1k	1.0k	798	781	753	217	4.7k
Fergus Macbeth United Kingdom	34	1.4k 0.7×	1.9k 1.8×	767 1.0×	224 0.3×	206 0.3×	108	4.3k
Eleftherios C. Vamvakas United States	42	587 0.3×	448 0.4×	1.1k 1.4×	1.1k 1.3×	225 0.3×	113	6.2k
Elisa Rossi Italy	29	2.1k 1.0×	2.2k 2.2×	599 0.8×	383 0.5×	346 0.5×	98	6.3k
Enric Carreras Spain	52	2.2k 1.0×	594 0.6×	514 0.6×	858 1.1×	293 0.4×	255	8.4k
Boris Nikolic United States	37	341 0.2×	1.4k 1.3×	1.7k 2.2×	283 0.4×	809 1.1×	94	5.3k
Baruch Brenner Israel	34	2.3k 1.1×	816 0.8×	1.0k 1.3×	332 0.4×	212 0.3×	158	3.8k
Xianglin L. Du United States	46	4.0k 1.9×	1.6k 1.5×	817 1.0×	963 1.2×	342 0.5×	216	7.4k
Howard M. Shulman United States	53	2.0k 0.9×	884 0.9×	1.2k 1.5×	707 0.9×	1.1k 1.4×	109	11.3k
Gaetano Ciancio United States	44	585 0.3×	1.8k 1.8×	3.2k 4.0×	239 0.3×	718 1.0×	363	7.2k
Victor S. Blanchette Canada	57	436 0.2×	1.6k 1.5×	2.0k 2.5×	1.3k 1.7×	607 0.8×	305	18.2k

Countries citing papers authored by Luigi Cavanna

Since Specialization

Citations

This map shows the geographic impact of Luigi Cavanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Cavanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Cavanna more than expected).

Fields of papers citing papers by Luigi Cavanna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Cavanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Cavanna. The network helps show where Luigi Cavanna may publish in the future.

Co-authorship network of co-authors of Luigi Cavanna

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Cavanna. A scholar is included among the top collaborators of Luigi Cavanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Cavanna. Luigi Cavanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Citterio, Chiara, Claudia Biasini, Camilla Di Nunzio, Giuliana Lo Cascio, & Luigi Cavanna. (2024). Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study. Vaccines. 12(1). 76–76.

Bianchini, Paolo, et al.. (2022). Targeted photoimmunotherapy for cancer. BioMolecular Concepts. 13(1). 126–147. 9 indexed citations

Bruno, Stefano, Paolo Bianchini, Alberto Diaspro, et al.. (2022). A photosensitizing fusion protein with targeting capabilities. BioMolecular Concepts. 13(1). 175–182. 2 indexed citations

Citterio, Chiara, et al.. (2022). Cure a casa: posizionamento di dispositivo venoso a domicilio per pazienti non autonomi durante la pandemia covid-19. Da attività in emergenza a pratica routinaria. Recenti Progressi in Medicina. 113(11). 669–673.

Delcanale, Pietro, Ana Moreno, Davide Lelli, et al.. (2022). The Interaction of Hypericin with SARS-CoV-2 Reveals a Multimodal Antiviral Activity. ACS Applied Materials & Interfaces. 14(12). 14025–14032. 24 indexed citations

Citterio, Chiara, et al.. (2021). Characteristics and outcomes of five patients with COVID‐19 and hematological malignancies. SHILAP Revista de lepidopterología. 9(6). e04013–e04013. 2 indexed citations

Cavanna, Luigi, Chiara Citterio, Camilla Di Nunzio, et al.. (2021). Le cure oncologiche ed ematologiche sul territorio secondo il modello dell’ASL di Piacenza. Rendiconto di 4 anni consecutivi. Recenti Progressi in Medicina. 112(12). 785–791. 2 indexed citations

Griguolo, Gaia, Maria Vittoria Dieci, Laia Paré, et al.. (2021). Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. npj Breast Cancer. 7(1). 12–12. 15 indexed citations

Aschele, C., Maria Emanuela Negru, Alessandro Pastorino, et al.. (2020). Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy. JAMA Oncology. 7(2). 304–304. 16 indexed citations

10.

Cuomo, Arturo, Marco Cascella, Cira Antonietta Forte, et al.. (2020). Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. Journal of Clinical Medicine. 9(4). 1003–1003. 34 indexed citations

11.

Cavanna, Luigi, et al.. (2019). La malattia cancro e la perdita del lavoro. Studio osservazionale prospettico su 416 pazienti oncologici con diagnosi di cancro e in attività lavorativa. Recenti Progressi in Medicina. 110(7). 356–363. 4 indexed citations

12.

Nanni, Oriana, D. Amadori, Andrea De Censi, et al.. (2018). Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Research and Treatment. 174(2). 433–442. 73 indexed citations

13.

Mordenti, Patrizia, et al.. (2018). La cura oncologica nel territorio. Esperienza nella Casa della Salute: risultati preliminari nella provincia di Piacenza. Recenti Progressi in Medicina. 109(6). 337–341. 2 indexed citations

14.

Dieci, Maria Vittoria, Antonio Frassoldati, Daniele Generali, et al.. (2017). Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials. Breast Cancer Research and Treatment. 163(2). 295–302. 20 indexed citations

15.

Musolino, Antonino, Fabio Falcini, Daniela Boggiani, et al.. (2017). Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. European Journal of Cancer. 88. 10–20. 3 indexed citations

16.

Roila, Fausto, Benedetta Ruggeri, Enzo Ballatori, et al.. (2015). Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Annals of Oncology. 26(6). 1248–1253. 24 indexed citations

17.

Passardi, Alessandro, Emanuela Scarpi, Stefano Tamberi, et al.. (2015). Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS ONE. 10(8). e0134732–e0134732. 35 indexed citations

18.

Cicilia, Roberto Di, Patrizia Mordenti, Elisa Anselmi, et al.. (2014). HER2-positive gastric cancer showing marked thickening of the gastric wall on ultrasonographic and computed tomographic scans. a chance phenomenon or a specific behaviour of this cancer type? Report of three cases.. PubMed. 34(9). 5083–6. 3 indexed citations

19.

Vallisa, Daniele, Luigi Cavanna, Raffaella Bertè, et al.. (1995). Autoimmune Thyroid Dysfunctions in Hematologic Malignancies Treated with Alpha-lnterferon. Acta Haematologica. 93(1). 31–35. 16 indexed citations

20.

Cavanna, Luigi, Giuseppe Civardi, Fabio Fornari, et al.. (1992). Ultrasonically guided percutaneous splenic tissue core biopsy in patients with malignant lymphomas. Cancer. 69(12). 2932–2936. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact